Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699236 | 0.83 | S1PR1 (0.48) | CYP1A2CYP2C19ENPP2LMNAS1PR1 | |
| SCHEMBL30407399 | 0.79 | DYRK1A (0.51) | CYP1A2CYP2C19TP53LMNAMAPT | |
| SCHEMBL569209 | 0.78 | NPSR1 (0.50) | CYP1A2CYP2C19TP53LMNAMAPT | |
| SCHEMBL19771403 | 0.76 | POLB (0.53) | CYP1A2CYP2C19ENPP2TP53LMNA | |
| SCHEMBL569392 | 0.75 | MAPT (0.43) | CYP1A2CYP2C19LMNAMAPTPOLB | |
| SCHEMBL569319 | 0.75 | RAB9A (0.45) | TP53LMNAMAPTTHRBPOLB | |
| SCHEMBL17966923 | 0.74 | ENPP2 (0.61) | CYP1A2CYP2C19ENPP2TP53LMNA | |
| SCHEMBL927333 | 0.71 | CYP1A2 (0.48) | CYP1A2CYP2C19TP53LMNAPDE4A | |
| SCHEMBL928327 | 0.70 | CYP1A2 (0.50) | CYP1A2CYP2C19LMNA | |
| SCHEMBL569384 | 0.69 | THRB (0.37) | ENPP2TP53LMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | CYP1A2 345/4885CYP2C19 605/4885ENPP2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.